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1. Introduction
In-transit melanoma is a unique pattern of recurrence that occurs in up to ten percent of pa‐
tients with melanoma. In-transit disease denotes multifocal tumor deposits occurring be‐
tween the site of the primary lesion and its regional draining lymph node basin [1, 2]. It is an
independent adverse prognostic factor and is frequently associated with distant metastasis.
This pattern of recurrence represents a challenging management problem, but provides
unique treatment modalities as well. In addition, studying in-transit melanoma has the po‐
tential to shed additional light on melanoma biology. The goal of this chapter is to discuss
the presentation, underlying disease biology, and various current treatment strategies for
this unique pattern of recurrence in melanoma.
2. Background
2.1. Nomenclature and staging
The nomenclature used for in-transit melanoma can be confusing, in part because a number
of different terms have traditionally been used in the literature to describe what is most like‐
ly the same oncologic process. Historically, terms such as locoregional recurrence, satellito‐
sis, and in-transit disease have all been used with varying definitions and intentions.
Historically, satellitosis has been defined as locoregional recurrence, not lying within the re‐
gional nodal basin, that is located within either 5cm of the initial lesion or 2cm of the exci‐
sion scar, whereas the term in-transit disease has been defined as such a recurrence
occurring at greater distances from the initial lesion or scar, respectively. In either case, such
lesions likely represent tumor deposits growing along routes of lymphatic drainage. More
recently, it has become apparent that for locoregional recurrence, distance from the primary
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lesion to the site of recurrence does not carry significant prognostic value [3-6]. Accordingly,
the most recent AJCC staging system for melanoma does not differentiate between in-transit
lesions and satellitosis in the assignment of stage, both being designated as N2 or N3 dis‐
ease, depending on regional node status [7]. Thus, in an effort to address the ambiguity aris‐
ing from nomenclature, many authors have advocated for eliminating the term satellitosis,
instead referring to all regional non-nodal metastatic disease as in-transit disease.
Stage T N M
IIIA Any depth,
Without ulceration
1-3 nodes (not clinically detectable) No distant disease
IIIB Any depth,
With ulceration
1-3 nodes (not clinically detectable) No distant disease
Any depth,
Without ulceration
1-3 nodes (clinically detectable), OR
in-transit lesions
No distant disease
IIIC Any depth,
With ulceration
1-3 nodes (clinically detectable), OR
in-transit lesions, OR
any combination of positive nodes and in-transit
disease, OR
greater than 4 positive nodes
No distant disease
Table 1. Breakdown of AJCC staging for stage III melanoma [7].
An additional and equally important point of clarification is the distinction between actual
local recurrence and in-transit disease. True local recurrence is defined as a primary tumor
that recurs as a result of incomplete primary excision, and is confined to or contiguous with
an excision scar and bearing an in situ component [8]. As this carries a much better progno‐
sis, it must be distinguished from potentially similar appearing in-transit disease found in
close proximity to a prior excisional scar.
2.2. Presentation
By definition, in-transit melanoma represents advanced stage disease, and such recurrences
are typically discovered months after the initial management of a primary lesion. In most
series, this disease-free interval to recurrence as in-transit disease ranges from 12-16 months
[9, 10]. The clinical presentation can be quite variable, but usually involves anywhere from
one to upwards of one-hundred small cutaneous or subcutaneous nodules. The lesions
themselves can differ significantly in size, ranging from sub-millimeter diameter to well
over one centimeter. They may take the form of superficial cutaneous (also called epidermo‐
tropic) or deeper subcutaneous tumors. For extremity-based disease, the lesions may be
clustered near the primary lesion, or may involve the entire extremity extending between
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the primary tumor and its lymphatic drainage basin. For non-extremity disease, the distribu‐
tion can be even more variable, with widespread tumor burden on the head, neck or trunk,
depending on the location of the primary melanoma.
Figure 1. Examples of in-transit melanoma of the arm (left) and leg (right). Note the distribution and extent of dis‐
ease, making these presentations very poor candidates for surgical excision. On the left, there is evidence of in-transit
metastases both within the area of previous skin flap, as well as extending more proximally along its course of lym‐
phatic drainage. On the right, there is extensive disease extending up to the inguinal crease.
2.3. Incidence
In-transit melanoma is a relatively uncommon phenomenon, with fewer than 10% of mela‐
nomas recurring as in-transit disease [1, 11]. This accounts for approximately 12-22% of all
recurrences, although this number is difficult to determine with accuracy due to ambiguity
regarding terminology used to describe local recurrence versus regional in-transit disease
[12-14]. Stage of disease appears to be the most important factor that predicts the develop‐
ment of in-transit metastasis. The presence of associated nodal disease significantly increas‐
es risk of in-transit recurrence, with one study reporting incidence as high as 31% when
three or more positive nodes were present [12]. Location itself also appears to be a factor,
with a higher incidence of in-transit disease in the lower extremities compared to the upper
extremities [15]. Of note, some earlier authors observed that surgical lymph node dissection
may lead to increased risk of recurrence as in-transit disease, an area of some debate. This is
postulated to be a result of lymphatic trapping, whereby dissection of the draining lymph
node basin removes the potential outflow of lymphatic tumor deposits, possibly leading to
increased likelihood of in-transit disease. In larger, more recent studies, however, neither
sentinel lymph node biopsy nor lymphadenectomy were found to have any effect on the in‐
cidence of in-transit metastases [16-19].
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2.4. Outcomes
The presence of in-transit metastases indicates either N2 or N3 status under the current
AJCC TNM system, and is classified as stage IIIB or C disease, respectively. In-transit mela‐
noma carries a poor prognosis, with 5-year survival rates ranging from 25% to 30% in most
reports [12, 20, 21]. Additionally, the presence or absence of regional lymph node disease is
of significant prognostic value; the combination of nodal metastasis and in-transit melano‐
ma comprise stage IIIC disease, which is associated with a poorer outcome than stage IIIB
(40% vs. 59% five-year survival, respectively) [7]. There is a high incidence of occult distant
metastasis in the presence of in-transit melanoma, but this is not universally the case. Stud‐
ies examining the outcomes of major amputation for the treatment of this pattern of recur‐
rence have identified a number of patients who experience a complete and durable response
and have demonstrated five-year survival rates ranging from 21-32% [22-26]. This indicates
that a significant minority of patients with in-transit metastases have disease that is truly
limited to the extremity at the time of detection. Nonetheless, it is essential that distant
metastases be ruled out when staging patients with in-transit melanoma, since treatment op‐
tions and prognosis may differ substantially when measurable distant disease is present.
3. Biology of in-transit disease
The underlying biology of in-transit melanoma is believed to be related to lymphatic dis‐
semination of small tumor emboli along the lymphatic drainage from the primary tumor. It
is generally accepted that these migrating tumor cells become trapped in the dermal and
subdermal lymphatics, typically, though not always, somewhere between the primary le‐
sion and the draining regional lymph nodes. These cells are thought to remain static along
this route, eventually progressing to a clinically detectable lesion. Consistent with this theo‐
ry, in-transit melanoma is often described as an ongoing process, with increasing disease
burden over time. Although the lymphatic route is the most likely biological explanation,
some authors have suggested other mechanisms. One alternate explanation describes in-
transit disease as a manifestation of systemic disease resulting from hematogenous spread,
similar to distant metastases [27, 28]. Proponents of this argue that in the lymphatic theory,
wider margins of primary excision would be expected to include more static occult cells,
with subsequent improved clinical outcomes, yet this has not been shown to be the case. It is
difficult to reconcile this theory, however, with the significant differences in survival ob‐
served in stage III versus stage IV melanoma.
4. Therapy for in-transit disease
Treatment of locoregionally recurrent melanoma depends on a number of important factors,
including tumor size, multiplicity, and anatomic location. Although in-transit melanoma is
often followed by metastatic disease, it is important that the surgeon choose an appropriate
therapy based on clinical presentation, history, technical experience, and patient preference.
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4.1. Local management
Distinguishing in-transit disease from true local recurrence is of great importance, as the
management and prognosis differ substantially. Local recurrence, or tumor confined to or
contiguous with an excision scar and bearing an in situ component, should be managed sim‐
ilarly to the primary lesion with wide local excision. For in-transit disease, however, it is
generally accepted that the wide local excision margin guidelines applicable to primary mel‐
anomas need not be applied. In-transit metastases are generally very clearly demarcated his‐
tologically from surrounding tissue, and complete macroscopic excision with negative
surgical margins is usually all that is required.
In addition to wide local excision, there has been significant interest in other forms of local
therapy for melanoma lesions, including laser ablation, external beam radiation, and intrale‐
sional injections. Irrespective of modality, these should all be thought of as equivalents to
local surgical excision regarding indications and prognosis.
Laser therapy was first described in 1973, and has gained favor in the local treatment of in-
transit disease that is not amenable to surgical excision, such as when the disease is too ex‐
tensive [29]. It is most useful in patients with a large number of small in-transit lesions, but
its advantages and utility decrease as lesions increase in size [30]. For tumors smaller than
approximately 3mm, the entire lesion can be ablated using a carbon dioxide laser, though
larger lesions must be circumscribed using the laser and subsequently excised with forceps.
Intralesional injections have also been used in the treatment of in-transit melanoma with
some  success.  The  most  commonly  used  therapies  include  bacillus  Calmette-Guérin
(BCG), dinitrochlorobenzene (DNCB), and interferon-alpha (INF-α), and IL-2. Small stud‐
ies  have demonstrated complete  response rates  of  31-63% (overall  response 45-91%),  al‐
though  long-term  survival,  when  reported,  remained  unfortunately  low  [31-33].  This
suggests that if surgical excision is not a viable option, intralesional injection is a reasona‐
ble alternative. More recently,  electrochemotherapy (ECT) has gained popularity as local
alternative to radiotherapy and laser ablation. This technique relies on using high intensi‐
ty electric pulses to allow intracellular delivery of cytotoxic drugs, such as cisplatin and
bleomycin, via intralesional injection [34]. Complete response rates have been reported as
53-89% (overall  response 84-99%),  with minimal systemic toxicity [35-37].  Unfortunately,
regardless  of  which  method is  employed,  local  management  of  in-transit  melanoma re‐
mains suboptimal in many situations.
4.2. Radiation therapy
Early in-vitro and clinical studies suggested that melanoma tumors exhibited significant in‐
trinsic resistance to ionizing radiation, and as such, radiotherapy has not traditionally been
considered to have a major role in the treatment of in-transit melanoma [38, 39]. More recent
studies, however, have suggested radiotherapy may be of value in certain subsets of indi‐
viduals, particularly those with one or few metastatic lesions that are not amenable to surgi‐
cal excision [40]. As a primary treatment, radiotherapy is largely reserved for palliation of
patients with incurable symptomatic lesions, particularly in cases that are not amenable to
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surgical excision. Generally speaking, when unresectable in-transit melanoma is amenable
to regional chemotherapy, this should be considered prior to employing radiotherapy.
While some studies have demonstrated potential benefit of adjuvant radiation therapy in
patients with nodal melanoma metastases, there are very little data regarding the use of ad‐
juvant radiation therapy in the setting of in-transit disease [41, 42]. Treatment depends on
area and location of involvement. While not routine practice, adjuvant radiotherapy should
be considered in patients with head and neck disease, and in those with positive margins
that are not amenable to re-excision [43-45].
4.3. Regional therapy
Given the high rate of local treatment failure and frequently increased burden of in-transit dis‐
ease, regionally focused modalities offer potential strategies to obtain more durable treatment
responses. Regional chemotherapy is a promising therapeutic option for suitable patients with
extremity in-transit melanoma and is currently the focus of exciting research. This modality in‐
volves vascular isolation of the affected area, after which chemotherapy is then delivered at
doses 10-20 times higher than doses that can be achieved and tolerated systemically, with dos‐
ing based on affected limb volume. As regional therapy requires complete vascular isolation of
the affected body area, obvious anatomic limitations are involved. The inflow and outflow ves‐
sels to the area of interest must be selectively cannulated, and the treatment region must then
be isolated from the systemic circulation, usually by means of a tourniquet.
There remains significant debate as to whether regional chemotherapy produces an overall
survival benefit over other therapeutic modalities, but studies have demonstrated a survival
benefit in patients who exhibited a clinical response [46-48]. Originally described in the
1950s, two primary forms of regional chemotherapy have evolved: hyperthermic isolated
limb perfusion (HILP) and isolated limb infusion (ILI).
HILP ILI
Drug delivery Cardiopulmonary bypass Manual pump with three-way stopcock
Circuit pressure High; with significant risk for systemic leak Low; significantly reduced risk of systemic
leak
Vessel access Open surgical exposure; large diameter
cannulas
Percutaneous access under fluoroscopic
guidance, smaller diameter cannulas
Limb pH Physiologic Acidotic
Limb oxygenation Active membrane oxygenation No external oxygenation; profound hypoxia
Temperature 39-40°C 37.8-38.5°C
Duration of treatment 60 minutes 30 minutes
Technical demand Technically complex, difficult re-operation Technically simpler, re-do operation without
difficulty
Table 2. Comparison of technique and parameters between hyperthermic isolated limb perfusion (HILP) and isolated
limb infusion (ILI).
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4.4. Regional chemotherapy agents
Melphalan is typically the drug of choice for regional chemotherapy. It is an alkylating
agent derived from phenylalanine, an amino acid preferentially taken up by melanocytes
due to its key role in melanin synthesis. Theoretically, melphalan should produce selective
toxicity in melanocytes and melanin-containing melanoma cells. As a systemic agent, how‐
ever, melphalan is ineffective despite its theoretical benefits, as its allowable dose is signifi‐
cantly less than its effective dose. For regional therapy, in contrast, this much higher
effective dose is achieved without systemic toxicity.
Other agents have been employed either alone or in combination with melphalan in the
treatment of in-transit melanoma. An essential quality of any agent considered for regional
therapy is the constraint that it must not require metabolic transformation to take on a bio‐
logically active form. Cisplatin is another alkylating agent that held significant promise in
preclinical studies of regional chemotherapy. Early clinical reports were favorable regarding
response rates, but were plagued by concerns over toxicity [49-51]. Subsequent studies con‐
firmed significant limb-threatening toxicity with the use of cisplatin, and as such most au‐
thors recommend against its routine use in regional therapy [52, 53]. Similarly, TNFα has
exhibited some potential, particularly when combined with interferon-gamma, but wide‐
spread use of TNFα-based regimens have been tempered by significant concerns regarding
toxicity [54]. The 2006 ACOSOG Z0020 trial comparing melphalan with melphalan plus
TNFα was terminated early after interim analysis demonstrated a significant increase in tox‐
icity with the addition of TNFα and yet a similar clinical response rate compared to melpha‐
lan alone [55]. Temozolomide is a newer alkylating agent that could have potential
application in regional chemotherapy, as it also does not require hepatic conversion to be‐
come active. Early results in animal models reported superior tumor growth delay com‐
pared to regional melphalan, and a phase 1 clinical trial is currently underway, enrolling
patients at Duke University Medical Center [56].
4.5. Isolated limb perfusion
Isolated limb perfusion (ILP) was first described in Creech and colleagues in 1958, basing
their technique on advances in cardiopulmonary bypass developed for cardiac surgery in
the 1950s [57]. They utilized an extracorporeal oxygenator as part of the isolated limb circuit
to deliver high dose chemotherapy while maintaining normal oxygen tension and pH of the
treated limb. Ten years later, Stehlin and coworkers added the effects of hyperthermia to the
treatment protocol, now called hyperthermic isolated limb perfusion (HILP), enhancing the
cytotoxicity of the chemotherapy and increasing efficacy [58]. The technical aspects of HILP
vary somewhat among surgeons and institutions, but the basic technique is similar.
The procedure is performed under general anesthesia, and the vasculature supplying the af‐
fected limb is exposed and cannulated. During this exposure, one typically performs a re‐
gional lymphadenectomy, which aids vascular exposure (particularly in the case of the iliac
vessels) and is often indicated from an oncologic standpoint. The target limb is isolated from
the systemic circulation using a proximal tourniquet. Perfusion is then initiated via the can‐
nulated vessels, utilizing a membrane oxygenator and cardiopulmonary bypass apparatus
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to maintain limb oxygen tension and pH at physiologic levels. The perfusion treatment is
generally continued for 60 to 90 minutes, depending on the protocol. External warming
blankets and heated melphalan perfusate are used to achieve hyperthermia. During HILP, it
is important to monitor for leakage of the perfusate into the systemic circulation, particular‐
ly when high dose TNF-alpha is employed, as systemic leakage can lead to significant mor‐
bidity or mortality. Traditionally this monitoring was performed using intravenous
fluorescein and watching for staining proximal to the tourniquet. A more precise method in‐
volves the administration of radiolabeled tracer into the HILP circuit, followed by continu‐
ously monitored systemic radiation exposure using a gamma probe placed over the chest.
After completion of chemotherapy perfusion, a 30-minute washout period with crystalloids
follows to remove the active agents.
Figure 2. Hyperthermic isolated limb perfusion. Surgical exposure of the proximal vasculature is followed by cannula‐
tion and circulation of chemotherapy perfusate. Acid-base status and oxygenation is maintained throughout the pro‐
cedure. Reproduced with permission.
Results of HILP vary widely, perhaps depending on the patient population and adjunctive
agents employed. In single-center studies, overall response rates of 81-100% and complete
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response rates of 39-82% [46, 48, 59-62] have been reported. However, the previously men‐
tioned multi-center ACOSOG Z0020 study demonstrated complete response rates of only
25%, significantly lower than what had been previously reported [55]. Overall, recurrence
rates are 50-60% within one year, and overall 5-year survival rates remain in the 30-40%
range [63]. As such, while HILP may be the best treatment option for suitable patients with
in-transit extremity melanoma, there remains significant room for therapeutic improvement.
Study (year) [ref] Patients (n) CR (%) PR (%) OR (%)
Minor (1985) [60] 18 82 18 100
Storm (1985) [62] 26 50 31 81
Di Filippo (1989) [59] 69 39 43 82
Cornett (2006) [55] 58 25 39 64
Sanki (2007) [48] 120 69 15 84
Raymond (2011) [61] 62 55 26 81
Table 3. Response rates following HILP in patients with in-transit melanoma. Adapted with permission from Coleman
et al., Expert Rev. Anticancer Ther. 2009;9(11):1599-1602. CR: Complete response; PR: Partial response; OR: Overall
response.
4.6. Isolated limb infusion
Isolated limb infusion (ILI) was developed by Thompson and coworkers at the Sydney Mel‐
anoma Unit as a less invasive alternative to HILP. This technique employs percutaneous
catheters inserted under fluoroscopic guidance as a means to cannulate the target limb ves‐
sels. An external tourniquet is used to isolate the limb, which is then wrapped in heating
blankets. The key difference with ILI as compared to HILP is the lack of a perfusion pump
and membrane oxygenator. The melphalan solution is instead manually circulated via the
arterial catheter using a syringe and three-way stopcock. Consequently, during ILI the limb
is not maintained at normal pH and oxygen tension, and becomes markedly hypoxic and
acidotic during the course of the procedure. Some authors propose that the acidosis and hy‐
poxia may serve to augment melphalan action [64]. In addition, while external and internal
warming are performed in ILI, limb temperatures achieved with ILI are lower than those in
HILP and generally do not exceed 38.5 degrees centigrade [65, 66].
From a technical standpoint,  ILI is appreciably simpler and easier to perform and learn.
The infusion treatment is continued for about 30 minutes, followed by a similar washout
period with crystalloid.  Lower doses of melphalan are typically used, often in combina‐
tion with dactinomycin, and regional morbidity is reduced, particularly with respect to in‐
cidence of severe toxicity. In light of these factors, ILI is generally well tolerated, and is
often offered to frail patients with multiple comorbidities who would not tolerate the lon‐
ger and more invasive groin exposure required for HILP. Along similar lines, due to its
simplicity and lower morbidity, ILI can be safely offered as a repeat procedure. Although
theoretically attractive as a means of obtaining fractionated regional chemotherapy, elec‐
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tive repeat ILI has not been shown to improve survival compared to single ILI [67]. How‐
ever,  repeat ILI can be very valuable in the management of recurrent or progressive in-
transit disease after primary regional therapy.
Figure 3. Isolated limb infusion. Catheters are placed percutaneously, and chemotherapy is circulated by hand with‐
out active oxygenation, leading to profound hypoxia and acidosis.
Outcomes after ILI are generally inferior to HILP, with complete response ranging from
23-44% and overall response ranging from 43-100% [47, 61, 65, 66, 68-70]. In one of the larg‐
est studies explicitly comparing patterns of recurrence, ILI was found to have both signifi‐
cantly higher probability of recurrence (85% vs. 65%) and shorter time to first recurrence (8
months vs. 23 months) as compared to HILP [71]. Notably, there was no statistically signifi‐
cant difference in overall survival between the two groups, although there was a trend in
favor of HILP.
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Study (year) [ref] Patients (n) CR (%) PR (%) OR (%)
Mian (2001) [70] 9 44 56 100
Lindner (2002) [66] 128 41 44 85
Brady (2006) [69] 22 23 27 50
Kroon (2008) [47] 185 38 46 84
Beasley (2009) [68] 128 31 33 64
Raymond (2011) [61] 126 30 13 43
Table 4. Response rates following ILI in patients with in-transit melanoma. Adapted with permission from Coleman et
al., Expert Rev. Anticancer Ther. 2009;9(11):1599-1602. CR: Complete response; PR: Partial response; OR: Overall
response.
4.7. Post-treatment complications
As a result of the high concentration of chemotherapies administered in regional therapy,
some degree of  tissue toxicity is  often seen.  Multiple  grading systems have been devel‐
oped to score regional toxicity after treatment, with one of the most prominent being that
developed by Wieberdink and colleagues. In this system scores range from Grade I, or no
evidence of significant reaction, to Grade V, representing reaction severe enough to war‐
rant possible amputation [72]. Up to 85% of patients will exhibit Grade I or II level of tox‐
icity, but as a result of careful drug dosing based on limb volume rather than total body
weight, fortunately overall less than 1% of patients develop Grade V toxicity [73]. While
the spectrum of toxicity is similar between patients undergoing ILI and HILP, the risk of
significant toxicity is greater among those undergoing HILP. Furthermore, HILP carries a
higher  risk  of  limb  loss  from  amputation  as  compared  to  ILI.  Regardless  of  modality,
most adverse reactions are transient, with almost all patients demonstrating some skin er‐
ythema and edema that peaks in the first month post-operatively. Rare but more serious
complications include severe muscle  toxicity  and the development of  compartment syn‐
drome, necessitating fasciotomy.
4.8. Amputation
Amputation is almost never indicated in the standard treatment of in-transit melanoma. As
mentioned previously, historical treatment of in-transit disease by means of limb amputa‐
tion has led to long-term survival rates of 20-30 percent, which would suggest that a signifi‐
cant minority of patients with locoregional disease have recurrence that is in fact confined
entirely to the affected extremity. Recent advancements in aggressive local management, re‐
gional therapy and systemic treatment have rendered extremity amputation obsolete except
for the most intractable disease, particularly in light of comparable five-year survival rates
among patients undergoing these therapies. Thus, amputation should generally only be of‐
fered with palliative intent or in patients who refuse or are not candidates for regional che‐
motherapy or other less morbid therapies [22, 26].
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4.9. Systemic treatment
While a comprehensive discussion regarding systemic therapy for the treatment of mela‐
noma is beyond the scope of this chapter, when appropriate this modality should be con‐
sidered in the management of in-transit disease. Systemic therapy is typically applied in
cases of in-transit disease in the presence of distant metastases – that is, stage IV disease
[74].  Similarly,  patients with non-extremity in-transit  metastases – such as in-transit  dis‐
ease involving the head and neck,  truncal  or genitalia – present a difficult  management
problem and are  often palliated best  with systemic  treatment  options.  Systemic therapy
should also be considered for in-transit metastases in patients with recurrent or progres‐
sive disease who are not  candidates  for  repeat  local  or  regional  therapy.  Unfortunately,
systemic therapy for the treatment of patients with advanced melanoma has historically
been quite poor. A large meta-analysis of 42 trials of systemic treatments demonstrating a
median progression free survival of 1.7 months with only 14.5% of patients being progres‐
sion-free at 6 months [75].  Despite this poor track record, newer approaches to systemic
treatment of regional disease may hold promise, including vascular regulating agents, sig‐
nal targeting therapies and immune modulation therapy.
Current strategies have focused on attempting to increase tumor sensitivity to chemother‐
apeutics, improve local drug delivery, or target apoptotic pathways in an attempt to aug‐
ment response to regional therapy. The BRAF enzyme inhibitor vemurafenib,  as well  as
the immune modulating anti-CTLA-4 antibody ipilimumab, have recently shown promise
in phase III trials,  although neither is likely to provide durable disease-free survival [76,
77]. Another newer agent is bevacizumab, a monoclonal antibody to vascular endothelial
growth factor (VEGF), which is believed to normalize immature and shunt-dominated tu‐
mor vasculature, leading to improved delivery of chemotherapeutics to tumor cells. A re‐
cent  preclinical  animal  study  demonstrated  that  systemic  treatment  with  bevacizumab
prior to regional therapy increased delivery of  melphalan to the tumors of  interest  [78].
Another vascular targeting agent of recent interest is ADH-1, a pentapeptide that targets
and disrupts N-cadherin adhesion complexes, which are predominantly expressed by mel‐
anocytes after malignant transition into melanoma [79, 80]. ADH-1 is believed to increase
blood vessel permeability, increasing chemotherapy drug delivery [81]. A recent phase II
clinical trial studying pre-treatment systemic ADH-1 administration prior to ILI with mel‐
phalan demonstrated a reassuring complete response rate of 38% and an overall response
rate of  60%, although no significant progression free survival  was appreciated [82].  The
role  of  all  of  these agents  as  systemic adjuncts  to  regional  chemotherapy remains to be
seen, and is being defined in ongoing trials.
5. Conclusions
In-transit melanoma is a distinctive form of tumor recurrence, and is an indicator of late-
stage disease. It is very distressing to patients, often requiring multiple treatments, proce‐
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dures and hospitalizations. As such, management of this disease can be challenging and
frustrating to clinicians as well. Similar to systemic melanoma, in-transit disease is notori‐
ously resistant to chemotherapy, and treatment outcomes remain unsatisfactorily poor. Lo‐
cal therapies often tout impressive initial response rates, but are plagued by recurrence.
Over the past half-century, advances have been made in regional approaches to chemothera‐
py, including isolated limb perfusion and isolated limb infusion. While some of these meth‐
ods have demonstrated limited success, significant improvements in patient outcomes will
require further advances in both regional and systemic treatment of melanoma.
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